Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment

PURPOSE: Vismodegib is a Hedgehog pathway inhibitor approved for the treatment of advanced basal cell carcinoma. Currently, the pharmacokinetics (PK) and safety of vismodegib in patients with hepatic dysfunction are unknown and are the objective of this study. METHODS: Patients with advanced solid m...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Chemother Pharmacol
Main Authors: Abou-Alfa, Ghassan K., Lewis, Lionel D., LoRusso, Patricia, Maitland, Michael, Chandra, Priya, Cheeti, Sravanthi, Colburn, Dawn, Williams, Sarah, Simmons, Brian, Graham, Richard A.
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5520972/
https://ncbi.nlm.nih.gov/pubmed/28523596
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-017-3315-8
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki